Canadian Cancer Trials Group Bulletins


American Society of Hematology Annual Meeting and Exposition

Several Canadian Cancer Trials Group abstracts will be presented at the 50th ASH Annual Meeting and Exposition
being held December 6-9, 2008 in San Francisco, California.

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Long-term outcome of the EORTC 20981 phase III randomized intergroup study
Marinus H.J. Van Oers, Martine Van Glabbeke, Liliana Baila, Livia Giurgia, Richard Klasa, Robert E Marcus, Max Wolf, Eva Kimby and Anton Hagenbeek.
Tuesday, December 9, 2008: 8:00 AM
Canadian Cancer Trials Group LY.7

The addition of rituximab eliminates the negative prognostic impact of PMBCL compared to DLBCL in young patients with CD20-positive aggressive lymphomas receiving a CHOP-like chemotherapy: Results of a subgroup analysis of the Mabthera International Trial Group (MInT) study
Marek Trneny, Michael Rieger, Anders Osterborg, Ruth Pettengel, Darrell J White, Devinder Gill, Jan Walewski, MD, Evelyn Kuhnt, Markus Loeffler, Michael Pfreundschuh, and Anthony D. Ho.
Tuesday, December 9, 2008: 8:45 AM
Canadian Cancer Trials Group MY.9

Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: The Canadian Cancer Trials Group MY.11 trial
Darrell J White, Nizar J Bahlis, Deborah C Marcellus, Andrew Belch, A. Keith Stewart, Christine Chen, Michael J Kovacs, David A Macdonald, Donna E Reece, Erica Harnett, Judy-Anne W Chapman, and Ralph M Meyer.
Sunday, December 7, 2008, 6:00 PM-8:00 PM

Tolerability and efficacy of bortezomib added to CVP-R for previously untreated advanced stage follicular lymphoma: Interim analysis of a phase II study by the Canadian Cancer Trials Group
Laurie H Sehn, David A Macdonald, Sheldon H. Rubin, Morel Rubinger, Kevin R Imrie, Judy-Anne W Chapman, Marina Djurfeldt, Lois Shepherd, Stephen Couban, and Michael Crump.
Canadian Cancer Trials Group LY.13
Saturday, December 6, 2008, 5:30 PM-7:30 PM

50th ASH Annual Meeting and Exposition
December 6-9, 2008
Moscone Center
San Francisco, CA